ERBB2 and breast cancer: Furthermore, loss of stromal Cav-1 has great predictive value in ER (+), PR (+), HER2 (+), and the so-called triple-negative breast cancer patients (ER(-)/PR(-)/HER2(-)).Concurrently instituted endocrine therapy does not influence its predictive value, making it a new universal or widely applicable breast cancer prognostic marker [37].